Proteomics on fast track to deliver simple endometriosis blood test
ASX-listed diagnostics innovator Proteomics International Laboratories plans to start a commercial roll-out of its groundbreaking, simple 'traffic light' diagnostic blood test for endometriosis within months, in the process revolutionising healthcare for the disease.
The company says its latest trial of its PromarkerEndo test has put it on a fast track to deliver the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls and costing the Australian economy nearly $10 billion.
Over the weekend, Proteomics released the results of its latest trial, involving 704 blood plasma samples, to leading medical specialists and researchers at the prestigious World Congress on Endometriosis in Sydney.
The trial used a diagnostic test consolidated from earlier prototype models to compare cases of endometriosis with general population controls and symptomatic patients.
Proteomics said the trial delivered stunning accuracy in diagnosing cases across all stages of the debilitating disease.
'This is a major step forward in making non-invasive endometriosis diagnosis a reality.'
Proteomics International Laboratories managing director Dr Richard Lipscombe
In a sector where a diagnosis has traditionally taken an average of seven years and involved a painful and invasive laparoscopy and tissue biopsy, this simple blood test is poised to flip the script entirely.
For the first time, doctors may soon swap the scalpel for a simple fingerprick blood test, with PromarkerEndo positioned to become the frontline tool in detecting endometriosis in symptomatic patients. PromarkerEndo uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having endometriosis. In validation trials, the test clocked an overall accuracy score of 0.92 and reached up to 98 per cent sensitivity in severe cases. It has a robust stage one accuracy performance of 89 per cent in early-stage disease, which is often the hardest to detect.
Proteomics International Laboratories managing director Dr Richard Lipscombe said: 'This is a major step forward in making non-invasive endometriosis diagnosis a reality. The advances support our commercialisation strategy and reinforce the potential for PromarkerEndo to become a standard part of the clinical diagnostic pathway.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
9 News
6 hours ago
- 9 News
Revolutionary late-stage melanoma treatment sees survival rates surge
Your web browser is no longer supported. To improve your experience update it here A revolution in the treatment of late-stage melanoma has been reached, with clinical trial results seeing surging survival rates. Doctors are confident the new therapy approach, which will be subsidised by the Pharmaceutical Benefits Scheme (PBS), will overhaul the treatment of many types of deadly cancers. A tumour the size of a golf ball saw death come knocking for Matthew Croxford. A revolution in the treatment of late-stage melanoma has been reached with clinical trial results seeing surging survival rates (Nine) "You think - is this it?" the 52-year-old father-of-two told 9News. "And I had a lot of things to still achieve in my life." Croxford was offered to take part in an Australian and Netherlands-driven trial. The new therapy has flipped the cancer paradigm on its head, by giving the body the best opportunity to activate its own cancer-fighting defences. "It's like the sniffer dogs that find the fruit and veg and drugs at the airport, they're trained against what they need to find," The Melanoma Institute's Professor Georgina Long said. "By giving immunotherapy before surgery, we train our immune system better against the cancer," she said. A new therapy has flipped the cancer paradigm on its head by giving the body the best opportunity to activate its own cancer-fighting defences. (Nine) Of the 423 patients with Stage 3 melanoma, one group received usual treatment with surgery first, then a single immunotherapy drug. That order was then flipped for the other group, who were given two immunotherapy drugs first to shrink the tumour before surgery. "Their chance of the melanoma coming back is next to zero - it's less than five per cent," Long said. Such revolutionary results have seen the treatment approved to be funded by the PBS - a world first. Matthew Croxford was offered to take part in an Australian and Netherlands-driven trial. (Nine) Australia has the highest rates of melanoma in the world, with one person diagnosed every 30 minutes and a life lost every six hours because of the disease. Advances in treatment like this shift a diagnosis that has often been a death sentence to promising odds of survival. "I'm effectively cancer-free, I have no side effects whatsoever, and I'm incredibly fortunate," Croxford said. "It's like the sniffer dogs that find the fruit and veg and drugs at the airport, they're trained against what they need to find," The Melanoma Institute's Professor Georgina Long said. (Nine) The radical overhaul of traditional treatment is now being explored for other cancers, including lung, triple-negative breast cancer, kidney, head and neck cancers. This new treatment for Stage 3 melanoma patients is to be listed on the PBS within months. national cancer health melanoma medicine PBS CONTACT US Property News: The last inner Sydney suburbs where houses cost under $2m.
Sky News AU
7 hours ago
- Sky News AU
Studies at Casey Research Station in Antarctica ‘more critical now than' ever
Casey Research Station Leader Andy Warton says the research at Casey Research Station and other Australian Antarctic stations is 'more critical now than it's ever been'. 'It's more critical now than it's ever been,' Mr Warton told Sky News Australia. 'The work that goes on, not just at this station, but at other Australian stations … it's absolutely critical work. 'We keep the stations alive.'
Sydney Morning Herald
7 hours ago
- Sydney Morning Herald
‘A bomb thrown into the middle of science': Trump cuts hurt Australian medical research
Australian medical research institutes are suspending projects on malaria, tuberculosis and women's health, as well as laying off staff, as they reel from the Trump administration's multibillion-dollar science cuts. The situation has drawn condemnation from Australian scientists. Burnet Institute director Professor Brendan Crabb likened the cuts to 'having a bomb thrown into the middle of science'. 'The world of science and research in all its forms … is undergoing a global seismic shift as a result of what the US is doing,' he said. 'I can't think of another circumstance since the end of World War II where things have been upended so profoundly.' Preliminary estimates from the Burnet Institute show that the US cuts have left a $1.2 million funding shortfall across the organisation's global health programs and collaborations. A spokeswoman said this had led to the suspension until 2030 of research projects involving malaria, harm reduction, tuberculosis and women's and children's health. Loading Professor James Beeson, a world-renowned malaria researcher from the Burnet Institute, said the cuts would put millions of lives at risk. Beeson pointed to research by the Malaria Atlas Project, which estimates that a complete freeze in US funding would lead to 15 million additional cases of malaria every year and 107,000 deaths. Maternal deaths, stillbirths, tuberculosis and HIV rates throughout the Asia-Pacific region and parts of Africa would also increase substantially over the next few years unless the funding cuts were reversed or replaced by other funding sources, he said.
